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Summary
Background Metabolic syndrome (MS) constitutes a major determinant of cardiovascular (CV) morbidity and 
mortality in adults. This phenomenon in women before menopause is attenuated by gonadal hormonal activity. 
After menopause the CV disease (CVD) incidence among women increases dramatically, and often overtakes the 
prevalence observed among men. Little is known about the CV-risk characteristic of early postmenopausal women in 
our country. Therefore the aim of our study was to investigate the frequency and distribution of metabolic syndrome 
components in early postmenopausal women residing urban-rural area in central Poland. 
Material and Methods All women aged 65–75 years, opted for one general practice form an urban-rural area in 
Central Poland were invited to participate. The anthropometric measures, blood pressure and blood sampling were 
performed. For the purpose of the study, the modified NCEP ATP III criteria for the diagnosis of metabolic syn-
drome were used. 
Results 59.5% of eligible women accepted the invitation. Additional 5.2% of randomly selected women from initially 
non-responders group were added to the investigated population. In the studied group only 15.7% had normal body 
weight and 82.4% met the criteria for abdominal obesity (92% according to IDF). 81.9% of women were characterized 
by hypertension, even more met the NCEP ATP III criterion for elevated blood pressure (BP) (91.5%). Only 24.2% of 
studied women were treated effectively; moreover, despite treatment with three antihypertensive drugs 17.4% hyperten-
sive women did not reach target BP values. Over one quarter of studied women suffered from diabetes mellitus, among 
whom 25.5% were not aware of the presence of the disease. Another 37.1% of women presented with prediabetic 
condition. Lipid disturbances were noted in the 25.3% and 18.4% of women for triglycerides (TG) increase and low 
HDL-C levels, respectively. According to modified NCEP ATP III criteria we were able to diagnose 58.8% of studied 
women with metabolic syndrome. Additionally, 31.9% of postmenopausal women were active cigarette smokers. 
Conclusions Metabolic profile of early postmenopausal women in central Poland is strikingly abnormal. High inci-
dence of metabolic syndrome is mainly determined by extremely prevalent increased blood pressure and abdominal 
obesity. With relation to all identified metabolic syndrome components, the strategy aimed at the improvement of 
body mass status, diabetes diagnosis and especially blood pressure control appear to be of highest priority.
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Background
Clustering of metabolic abnormalities common-
ly known as metabolic syndrome (MS) constitutes 
a major determinant of prevalent cardiovascular 
(CV) morbidity and mortality in adults [1]. How - 
ever, this relationship in women before the meno-
pause is markedly attenuated by gonadal hormonal 
activity. Therefore, over past decades a special em-
phasis was put on the exploration of the interrela-
tionships between CV risk factors and CV conse-
quences predominantly in men. Declining gonadal 
hormonal activity in women coincides with a dra-
matic increase in CV risk [2] which is usually un-
derestimated by health-providers. Hypoestrogenism 
exert a negative impact on adipose tissue metab-
olism which along with physical inactivity favour 
central-body obesity development [2–4]. In turn, 
abdominal obesity via hormonal and molecular ac-
tions [5] is further implicated in the pathogenesis 
of hypertension, type 2 diabetes and dyslipidaemia. 
Consequently, women after menopause not only 
start to overtake men with different CV diseases 
but often CV-morbidity becomes overrepresented 
as compared to their male-counterparts. One of the 
strongest determinants accountable for the observed 
increase in CV disease (CVD) in postmenopausal 
women may be exceedingly prevalent and poorly 
controlled hypertension. High blood pressure itself is 
a leading cause of cerebrovascular events [6] as well as 
the premature deaths in the westernized societies [7]. 
Except for some epidemiological aspects [8], little is 
known about the specific characteristic of early post-
menopausal hypertension in women in our country. 
Data related to difficult-to-control or resistant hy-
pertension in this group of patients are also sparse. 
Therefore we sought to investigate the frequency and 
the distribution of metabolic syndrome components 
in early postmenopausal women residing urban-rural 
area in central Poland with special emphasis put on 
blood pressure control. 
Material and methods
To conduct the study we invited all women aged 
65 to 75 years old who at time of the recruitment 
(2013) dwelled the urban-rural Gniewkowo Coun-
ty in Central Poland (urban-rural population ap-
proximately 50%-to-50%), and had opted a family 
medical service. None of the health-related condi-
tion was an exclusion criterion from the study. Fol-
lowing the initial assessment of all responders, an 
additional weighted sample was recruited from the 
group of eligible women who did not accept primary 
invitation. In order to select a non-responder rep-
resentatives we performed a sample size calculation 
based on the power analysis. The assumption for 
the power analysis was primary based on the effect 
of the BMI status as the body fat translates to com-
plex metabolic disturbances commonly clustering in 
metabolic syndrome. Accordingly, additional group 
of randomly selected 33 women received repeated 
invitation, which was finally accepted by all of them.
The clinical assessment of study participants con-
sisted of anthropometric measurements that is body 
weight, waist circumference, height, body mass index 
(BMI); office blood pressure measurements (average 
of the second and the third measurement according 
to ESH); blood sampling (responders only) i.e. lipid 
profile, fasting blood glycaemia, and oral glucose tol-
erance test in all cases where fasting plasma glucose 
levels were equal or greater than 5.5 mmol/L and 
the participant denied established diabetes. For the 
purpose of our study we incorporated the definition 
of metabolic syndrome according to modified NCEP 
ATP III criteria [9, 10]. The presence of the three of 
the following criteria allowed for the MS diagnosis 
i.e. waist circumference ≥ 88 cm, triglycerides lev-
els ≥ 150 mg/dL (1.7 mmol/L), reduced HDL-C 
less than 50 mg/dL (1.3 mmol/dL), elevated BP ≥ 
130 mm Hg for systolic and/or ≥ 85 mm Hg 
of diastolic blood pressure, and elevated fasting plas-
ma glucose above 100 mg/dL (5.5 mmol/L) or estab-
lished diabetes mellitus. All participants gave written 
consent for data collection and analyses. 
Statistical analysis
All data were tabulated in MS Excel and computed in 
Statistica 10, StatSoft Inc. (licenced to Medical Uni-
versity of Gdansk). Data were averaged and presented 
as means ± SD and/or medians (IQR), if appropriate. 
Between-group comparisons were performed using 
unpaired t-test or Mann-Whitney tests, where ap-
propriate. The prevalence of particular disorders was 
presented as per cent. Power analysis was performed 
to estimate a sample selected from a non-responder 
group. P-value less than 0.05 was considered valid for 
all calculations.
Results
A total of 364 participants were initially enrolled 
in the study (59.5% response-rate) which together 
with additional randomly selected 33 women ac-
counted for 62.6% of a total eligible population. 
The clinical characteristic of the study group is pre-
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Figure 1. BMI status
Figure 2. Blood-lowering treatment efficacy in the complete stu-
died population of the postmenopausal women (both aware and 
unaware of hypertension). Data presented as per cent 
HTN — hypertension; BP — blood pressure
Table I. Clinical characteristic of the study group (n = 364)
Age (years) 69.2 ± 3.3
Weight (KG) 76.1 ± 13.6
BMI [KG/m2] 30.7 ± 5.3
Waist [cm] 98.0 ± 12.4
Total Cholesterol [mg/dl] 214.5 ± 49.0
LDL [mg/dl] 124.2 ± 45.0
HDL [mg/dl] 65.9 ± 17.6
Triglycerides [mg/dl] 127.4 ± 65.0
Glucose [mg/dl] 109.9 ± 28.3
Serum creatinine [mg/dl] 0.7 ± 0.2
eGFR (MDRD) 83.7 ± 23.4
eGFR (Cockcroft-Gault) 90.1 ± 24.8
eGFR (EPI) 82.0 ± 15.9
Systolic BP [mm Hg] 150.2 ± 22.1
Diastolic BP [mm Hg] 83.7 ± 10.4
No. of antihypertensive drugs 1.7 ± 1.4
No. of MS components 3.1 ± 1.1
BMI — body mass index; LDL — low density lipoprotein; HDL — high density lipoprotein;  
eGFR — estimated glomerular filtration rate; MDRD — Modification of Diet in Renal Disease equation; 
MS — metabolic syndrome
sented in Table I. Neither BMI nor blood pressure 
differed significantly in non-responder vs. respond-
er group. 
Based on the BMI analysis, only 15.7% of women 
had a normal body weight and vast majority (82.4%) 
met the NCEP ATP III criteria for the diagnosis of 
abdominal obesity (92% according to IDF). Detailed 
BMI distribution is presented in Figure 1. 
Similar fraction of studied women (81.9%) was 
characterized by hypertension i.e. either de novo 
(13.1%) or established hypertension. Even more 
met the NCEP ATP III criterion for elevated blood 
pressure (91.5%). Although the average duration of 
hypertensive disease was 11.4 ± 9.2 years, women 
who were aware of the diagnosed hypertension were 
treated effectively only in 24.2% (Figure 2). The 
distribution of the number of antihypertensive drugs 
was as follows: none — 27%, one drug — 19%, two 
drugs — 27%, three drugs — 16%, four drugs — 
10%, and five drugs — 2%. Specific percentage of 
blood-lowering drugs usage is presented in Figure 
3. A fraction of 17.4% hypertensive women did not 
reach target blood pressure values of < 140 mm Hg 
for systolic and/or < 90 mm Hg for diastolic lev-
els despite treatment with three anti-hypertensive 
medicines including a diuretic. The mean values of 
systolic blood pressure were tightly related to quan-
tity of clustering metabolic syndrome components 
(Figure 4).
A considerable number of studied women (25.8%) 
suffered from diabetes mellitus, among whom 25.5% 
were not aware of the presence of the disease (newly 
diagnosed cases accounted for 6.6% of the studied pop-
ulation). Another 37.1% of women presented with one 
or two of the prediabetic condition — Figure 5. 
The total cholesterol (TC) in statin-treated wom-
en equalled 196 ± 48.6, and LDL-C = 107.3 ± 46.0 
which was significantly lower comparing to the re-
sults seen in untreated women: 226.3 ± 44.2, and 
137.9 ± 39.2 for TC and LDL-C, respectively. How-
ever, the HDL-C and triglycerides (TG) were com-
parable in both groups 66.3 ± 17.4 vs. 65.5 ± 17.9, 
P = 0.66; and 130.0 ± 69.3 vs. 124.1 ± 59.2, P = 0.39 
for untreated vs. treated with lipid-lowering agents, 
respectively. 
The prevalence of metabolic syndrome and the 
distribution of its components are presented in Fig-
ure 6 and Figure 7.
Additionally, 31.9% of postmenopausal women 
were active cigarette smokers. 
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Discussion
The main message from our study is that metabolic syn-
drome is extremely prevalent in early postmenopausal 
years in an urban-rural female population in central 
Poland. Evidently, high blood pressure and abdominal 
obesity are the main determinants of this phenomenon. 
Body fat excess, especially with its abdominal dis-
tribution together with low physical activity consti-
tute main causative factors for the increased insulin 
resistance followed by the development of metabolic 
syndrome [11]. Clustering of metabolic abnormali-
ties has in turn deleterious influence on cardiovas-
cular profile, and significantly determines increased 
morbidity and mortality in westernized societies. 
Figure 4. Relationship of the number of antihypertensive drugs 
with systolic blood pressure values. One-way ANOVA, P < 0.001
Figure 6. Prevalence of Metabolic Syndrome in women aged 65-
to-75 years 
MS — Metabolic Syndrome
Figure 3. Antihypertensive drugs distribution  
ACEI — angiotensin converting enzyme inhibitors; CCB — calcium channel bloc-
kers; ARB — angiotensin receptor blockers; CNS — central nervous system
Figure 5. Glycaemia control 
IFG — impaired fasting glucose; IGT — Impaired glucose tolerance
A meta-analysis of data exploring the impact of MS 
on cardiovascular system which included a total of 
172,573 patients showed that MS increases the risk 
of cardiovascular events by 1.78-fold, and this rela-
tionship is even more evident in female patients (RR 
= 2.63) [12]. 
In the procreative age, cardiac saving-effect as-
cribed to female sex-hormones determines the gap 
in the incidence of cardiovascular disease reported 
in both genders. Although women start to over-
take men with different CV diseases after menopause 
[13]; this phenomenon may be only partially ex-
plained by gonadal function decline. Our cross-sec-
tional study clearly shows that soon after the onset 
of their menopause majority of women (58.8%) 
arterial hypertension 2015, vol. 19, no. 2
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Figure 7. Metabolic Syndrome components frequency distribution 
in postmenopausal women (age range from 65 to 75 years). Data 
presented as per cent 
meet the criteria of metabolic syndrome. It is thus 
justified to hypothesize that MS constitutes one 
of the substantial negative determinants account-
able for increased cardiovascular disease rate and 
premature deaths seen in postmenopausal women 
in Poland. In addition, there is an alarming trend 
recorded in the prevalence of MS in women. The 
WOBASZ study data which were published 10 
years ago [14] documented 46.3% of incident MS 
in women aged 60–75 years. The discrepant results 
between WOBASZ study and our analysis (46.3% 
vs. 58.8%; respectively) may result from several 
factors. Five years of difference for the entry cri-
teria may be partially accounted for the observed 
difference, since WOBASZ Study clearly showed 
stepwise increase in the incident MS in women 
across different age-subgroups. Second, as reported 
in WOBASZ Study, there are marked differences in 
the prevalence of MS crosswise voivodeships of Po-
land. Accordingly, the voivodeship we studied was 
one with the highest MS rate seen in 2005.
Third, and probably the most important, is the 
fact that the epidemiology of metabolic disturbances 
shows growing number over past decades in Po-
land. Recently announced data from NatPOL 2011 
Study documented slightly higher prevalence of MS 
in women in comparable age (60 to 79 years) as we 
report now (63% vs. 58.8%, respectively), which 
contrasts with the data from WOBASZ Study 2005 
(46.3%). Most probable scenario is that one of the 
main determinants of the development of MS is the 
growing epidemic of abdominal obesity [15].
Blood pressure
In the studied population, approximately 18% of 
females were not aware of having the indication to 
blood-lowering therapy (13.1% of newly diagnosed 
hypertension and 5% not treated), and vast majority 
(57.7%) who were on current treatment did not 
reach target blood pressure values. However, our 
data show a comparable percentage of effectively 
treated patients as reported in NatPOL Study in 
2011 (both sexes) i.e. 24.2% vs. 26%, respectively. It 
is not clear why only a fraction of 24.2% of women 
in postmenopausal age with established hyperten-
sion is characterized by satisfactory blood pressure 
control regardless of multiple and modern antihy-
pertensive drug regimens (Figure 2, 3). In addition, 
as many as 17.4% of postmenopausal hypertensive 
female patients do not reach target blood pressure 
levels irrespective of three blood-lowering medicines, 
including diuretics. The difficulties with hyperten-
sion control in this population raise a valid question 
about a real cause of this phenomenon. The design 
of our observational study did not allow us to verify 
the actual reason of unsatisfactory BP levels, how-
ever, the poor adherence to prescribed treatment 
regimen probably explains only part of the problem. 
It is also unlikely that secondary causes of hyperten-
sion account for such a poor outcome. In general, 
the mechanisms why women after the menopause 
have relatively higher incident hypertension com-
paring to men [16] is not well understood, especially 
that women are more likely to adhere to therapeutic 
regimens. National Statistics in the United Stated 
documented that more than 75% of women aged 
60 years old or older become hypertensive [13]. One 
may speculate that extremely high metabolic syn-
drome incidence (58.8%) via complex mechanisms 
significantly enhance blood pressure levels. Figure 5 
depicts an evident interdependence between the in-
creasing systolic blood pressure values and the num-
ber of clustering metabolic syndrome components. 
A reasonable explanation for these relationships may 
be extrapolated from studies in obstructive sleep ap-
noea (OSA). OSA has been attributed to abnormal 
diurnal blood pressure control, increasing odds for 
hypertension development, and difficulties in blood 
pressure lowering with pharmacological treatment. 
Since obesity is the major risk factor for the deve-
lopment of OSA, the concurrence of sleep disordered 
breathing and metabolic disturbances is very com-
mon. In fact, it is estimated that metabolic distur-
bances are approximately 9-times more likely to be 
present in subjects with OSA [17]. This hypothesis 
may be further supported by the observation that 
women after procreative age are more likely to deve-
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lop a nondipping pattern of diurnal BP [18] com-
paring to their male counterparts. Such abnormal 
blood pressure profile is a common characteristic in 
sleep apnoea [19]. 
Glycaemia control
International Diabetes Federation estimates that pa-
tients with MS are characterized by 5-fold increased 
risk for the development of type 2 diabetes, a condi-
tion which negatively influences estimated life-span 
and its quality. In our study, 25.8% of postmeno-
pausal women had already established type 2 diabe-
tes diagnosis, among whom 25.5% were not aware 
of this burden. This result fairly corresponds with 
prevalent type 2 diabetes mellitus recently reported 
by Authors of NatPOL 2011 [20] (25–30% in sub-
jects aged > 65 years). As a significant fraction of all 
diabetic women from Gniewkowo-County were not 
aware of the presence of the disease (25.5%), it ap-
pears that the implementation of systematic screen-
ing programs is critical in order to better identify the 
population at high and/or very high cardiovascular 
risk according to risk stratification strategies [21]. 
Another 37.1% of the postmenopausal women 
met the criteria of the prediabetic state (IFG and/ 
/or IGT). Taking into account the phenotype of 
the studied group (82.4% with abdominal obesi-
ty), one may speculate that a considerable fraction 
of prediabetic women will further progress to overt 
type 2 diabetes mellitus, unless prompt and complex 
preventive measures are introduced to stop this mod-
ifiable sequel.
Lipids
The analysis of lipid profiles in dichotomized sub-
groups documented clinically relevant net difference 
in total cholesterol and LDL-C levels in postmeno-
pausal female population, which may be account-
ed for the common use of statins. In our sample, 
44.4% of women were administered with statins, 
which is considerably higher than recently report-
ed by NatPOL Investigators (32% in subjects aged 
60–79 years) [22]. Consequently, widespread treat-
ment with lipid-lowering drugs allowed to reach the 
reasonable mean level of LDL-C equal 107.3 ± 46.0 
which is close to target LDL-C levels < 100 mg/dL 
(2.5 mmol/dL) recommended in patients at high 
cardiovascular risk (excluding diabetics and CV com-
plicated patients [23]). The residual risk, which is 
partially ascribed to elevated triglycerides and low 
HDL-C levels, appears to be less important than 
hypercholesterolaemia in this population. Mean val-
ue of TG was 127.4 ± 65.0 (target < 150 mg/dL) 
and HDL-C = 66 mg/dL for in the whole group of 
postmenopausal women (Table 1). Nonetheless, it is 
worth underlining that a fraction of approximately 
25% and 18% met the criteria of hypertriglyceridae-
mia and/or low HDL-C, respectively. 
Study limitations
The clinical data presented in our study are derived 
from the population who already had health-related 
records in Gniewkowo County; therefore no infor-
mation from women who did not opt primary care 
was available. It is possible that women who have 
never sought any sort of medical assistance are by 
definition healthier; however, from the statistical 
standpoint, one may assume that the distribution of 
subjects who are healthy vs. non-healthy etc. is bal-
anced. Additionally, the efficacy of the recruitment 
(final response-rate at 62.6%) closely reflects the ra-
tio achieved in the largest epidemiological studies 
completed in Poland (NatPOL 2011 response-rate 
at 66.4% [24]). 
Conclusions
Metabolic profile of early postmenopausal women 
dwelling in central Poland is strikingly abnormal. 
High incidence of metabolic syndrome is mainly 
determined by extremely prevalent hypertension and 
abdominal obesity. With relation to all identified 
metabolic syndrome components, the strategy aimed 
at the improvement of body mass status, diabetes 
dia gnosis and especially blood pressure control ap-
pear to be of highest priority in postmenopausal wom-
en in Poland. 
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